Literature DB >> 22198665

A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients.

Yan Geng1, Wei Zhou, Zhuo-Li Zhang.   

Abstract

To investigate the similarities and differences in clinical features between the sero-negative and sero-positive rheumatoid arthritis (RA) patients. Two hundred and sixty-two RA patients who fulfilled the 1987 ACR RA Classification Criteria were enrolled into this study. They were divided into sero-negative and sero-positive group depending on the presence or absence of rheumatoid factor (RF) and anti-cyclic citrullinate peptide (anti-CCP). The clinical features were compared between these two groups. Forty-six (17.6%) RA patients were classified as sero-negative group. The disease onset of sero-negative RA patients was later than that of sero-positive RA patients (52.4 ± 15.9 vs. 47.4 ± 15.5 years, P < 0.05). At the end of the first 2 years after disease onset, bone erosion shown in the hand X-ray occurred in 4 out of 24 (16.7%) patients with sero-negative RA. However, only 5.2% (5/97) patients with sero-positive RA developed bone erosion (P < 0.05). In the sero-positive RA patients, the titer of RF was correlated with swollen joint counts (SJC), tender joint counts (TJC), erythrocyte sedimentation rate (ESR), and disease activity score in 28 joints (DAS28) (P < 0.05), but anti-CCP was not. Sero-negative and sero-positive RA are probably two distinct disease subtypes driven by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198665     DOI: 10.1007/s00296-011-2329-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  Heart valve disease in seronegative rheumatoid arthritis.

Authors:  C S Carr; J C Roxburgh
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

2.  Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study.

Authors:  M Bukhari; B Harrison; M Lunt; D G Scott; D P Symmons; A J Silman
Journal:  Arthritis Rheum       Date:  2001-06

3.  Citrullination in extra-articular manifestations of rheumatoid arthritis.

Authors:  T Bongartz; T Cantaert; S R Atkins; P Harle; J L Myers; C Turesson; J H Ryu; D Baeten; E L Matteson
Journal:  Rheumatology (Oxford)       Date:  2006-06-16       Impact factor: 7.580

4.  Rheumatoid factor is a marker of disease severity in Korean rheumatoid arthritis.

Authors:  Yoo Seob Shin; Jeong Hee Choi; Dong Ho Nahm; Hae Sim Park; Jae Hyun Cho; Chang Hee Suh
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

5.  A comparison of patients with seropositive and seronegative rheumatoid arthritis.

Authors:  J Edelman; A S Russell
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

6.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.

Authors:  Henrike van Dongen; Jill van Aken; Leroy R Lard; Karen Visser; H Karel Ronday; Harry M J Hulsmans; Irene Speyer; Marie-Louise Westedt; André J Peeters; Cornelia F Allaart; René E M Toes; Ferdinand C Breedveld; Tom W J Huizinga
Journal:  Arthritis Rheum       Date:  2007-05

7.  Diagnostic value of anti-cyclic citrullinated peptide antibodies in northern Chinese Han patients with rheumatoid arthritis and its correlation with disease activity.

Authors:  Hui Li; Wuqi Song; Yang Li; Yanhong Liu; Jing Bai; Xiu Li; Fengyun Mu; Yao Wang; Fengshan Zhang; Liju Su; Fengmin Zhang
Journal:  Clin Rheumatol       Date:  2010-01-05       Impact factor: 2.980

8.  High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis.

Authors:  K Suzuki; T Sawada; A Murakami; T Matsui; S Tohma; K Nakazono; M Takemura; Y Takasaki; T Mimori; K Yamamoto
Journal:  Scand J Rheumatol       Date:  2003       Impact factor: 3.641

9.  Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations.

Authors:  L De Rycke; I Peene; I E A Hoffman; E Kruithof; A Union; L Meheus; K Lebeer; B Wyns; C Vincent; H Mielants; L Boullart; G Serre; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

10.  Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga
Journal:  Arthritis Res Ther       Date:  2005-06-14       Impact factor: 5.156

View more
  3 in total

1.  Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study.

Authors:  Sangtae Choi; Kwang-Hoon Lee
Journal:  PLoS One       Date:  2018-04-06       Impact factor: 3.240

2.  Patients with seronegative rheumatoid arthritis have a different phenotype than seropositive patients: A clinical and ultrasound study.

Authors:  Natalia Carbonell-Bobadilla; Carina Soto-Fajardo; Luis M Amezcua-Guerra; Ana Beatriz Batres-Marroquín; Tania Vargas; Adrian Hernández-Diazcouder; Valentin Jiménez-Rojas; Ana Cristina Medina-García; Carlos Pineda; Luis H Silveira
Journal:  Front Med (Lausanne)       Date:  2022-08-16

3.  A new tool for early diagnosis of rheumatoid arthritis using combined biomarkers; synovial MAGE-1 mRNA and serum anti-CCP and RF.

Authors:  Al-Qtaitat Aiman; Mwafi Nesrin; Albtoosh Amal; Al-Dalaien Nassar
Journal:  Pan Afr Med J       Date:  2020-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.